Emergent BioSolutions Inc. reported $770M of revenue over the trailing twelve months, −9.6% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $770M (to Q2 2026). Net income: −$177M, trailing twelve months to Q2 2026. Free cash flow: $86M, trailing twelve months to Q2 2026. Operating margin: −8.1%, trailing twelve months to Q2 2026.

EBSEmergent BioSolutions Inc.

Healthcare

$6.24-34% 1Y

$6.24

$4.4552 weeks$13.90

EBS as reported

Emergent BioSolutions Inc. reported $770M of revenue over the trailing twelve months, −9.6% on the year before. 11 reported series are charted on this page, each one as filed.

$770M

Revenue, trailing twelve months · to Q2 2026 · −9.6% against the twelve months before

Net income: −$177M
Net income · −227% year on year · trailing twelve months to Q2 2026
Free cash flow: $86M
Free cash flow · −45% year on year · trailing twelve months to Q2 2026
Operating margin: −8.1%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for EBS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$770M	−9.6%	Q2 2026
Net income	−$177M	−227%	Q2 2026
EPS	−$3.47	−241%	Q2 2026
Gross margin	55%	n/a	Q2 2026
Operating margin	−8.1%	n/a	Q2 2026
Net margin	−22%	n/a	Q2 2026
ROE	−7.6%	n/a	Q2 2026
ROA	−1.8%	n/a	Q2 2026
ROIC	4.2%	n/a	Q2 2026
Free cash flow	$86M	−45%	Q2 2026
P/E	18.5	n/a	Q3 2022 · 15 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.